Company intelligence / Profile preview
Thrombolytic Science International
Cambridge, Massachusetts, United Statestsillc.net ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company completed a Phase 1 clinical study confirming the safety and tolerability of its novel tPA/HisproUK dual regimen. Currently testing its dual regimen in a Phase 2 clinical trial in ischemic stroke patients. FDA cleared IND application for mutant prourokinase in September 2024. Following promising Phase II results from the DUMAS trial in stroke patients in the Netherlands, advancing to a Phase II trial in the UK for myocardial infarction following MHRA approval.
- Therapeutic areas
- HematologyCardiovascular
- Modalities
- EnzymeBiotherapyDual thrombolytic therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on Thrombolytic Science International.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Thrombolytic Science International.